AzTrials
AzTrials

HealthyPhase 1LowozNCT00468221

The Effect of Low Level Ozone Exposure on Healthy Volunteers

A Phase 1 study testing Ozone Exposure in people with Healthy, run by University of North Carolina, Chapel Hill.

Withdrawn

Withdrawn. The study stopped before anyone enrolled.

Official record
Search all trials

Trial summary

The purpose of this research study is to learn more about the effects of 0.12 ppm ozone exposure on humans. We know from other studies that exposure to levels of ozone that are seen on bad air pollution days, can cause an increased risk of illness and even death in some people with certain health problems like asthma… Read more about this study

Who is it for?
Ages 18 to 40 yearsHealthy volunteers can take part
Conditions the study is for
Healthy
What is being tested?
Ozone Exposure
How many people
0 participants
Where
No sites listed yet
Study dates
Jun 2009to Nov 2009
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 40 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Healthy Adult
  • Nonsmoker
  • Able to perform light exercise

Who cannot join

  • Asthma
  • active allergies
  • chronic disease

About this study

The purpose of this research study is to learn more about the effects of 0.12 ppm ozone exposure on humans. We know from other studies that exposure to levels of ozone that are seen on bad air pollution days, can cause an increased risk of illness and even death in some people with certain health problems like asthma and heart disease. We also know from studies we have done in our lab that even healthy people can have an inflammatory (an increase in the amount of bacteria fighting cells) response to high levels of ozone. We suspect that exposure to low levels of ozone makes the body more susceptible to things like allergens. For instance, in persons allergic to pollen, exposure to ozone in the environment may cause them to have more allergy symptoms when they are around pollen than they would have if they were not exposed to ozone first. In this study we are looking to find the lowest level of ozone to which healthy people can be exposed without seeing that increased immune response. We will use 0.12 ppm ozone; this is roughly the amount of ozone you would be exposed to on a "yellow" ozone day in the triangle area in the summer if you spent the entire day out of doors and exercising moderately.

Read the detailed description

Low levels of both endotoxin and O3 have been reported to prime airway responses for other stimuli, with a notable example being the immediate and late phase response to allergen. Likewise, epidemiological studies indicate that levels of O3 below the current air quality standards for ozone are still linked with exacerbation of respiratory tract disease. On a cellular level, both endotoxin and oxidants can prime inflammatory cells such that response to subsequently inhaled stimuli is enhanced. This has led to the idea that ozone may also enhance response to endotoxin and the reverse. As shown in our preliminary data, we have carefully examined the response to low levels of inhaled endotoxin and have found that a dose of 10,000 EU enhances the phagocytic function of macrophages, monocytes and PMNs and modifies the expression of cell surface receptors (CD11b, CD14), and alters IL-13 levels in sputum without causing PMN influx to the airway. This study is similar in design, but will evaluate the effects of ozone at a lower exposure level instead of endotoxin.

It has been thought that monocytes and macrophages did not mediate response to ozone because macrophages recovered from the airways of persons exposed to ozone had blunted responses to stimuli such as opsonized zymosan or other ligands, and in vitro, exposure of macrophages to ozone likewise renders them hypo-responsive to other stimuli, including endotoxin. There is general agreement that the airway response to endotoxin is mediated primarily by actions on macrophages and monocytes. However, monocytes undergo adaptation to endotoxin with previous challenge with endotoxin, and the chronic presence of endotoxin (i.e. in sepsis) also induces tolerance to the effect of additional exposure to endotoxin. Thus, suppression of monocyte/macrophage function by ozone may not be adequate evidence that these cells do not participate in ozone-induced airway inflammation.

It has also been argued that because ozone causes epithelial cells to generate mediators like IL-8 which is a potent chemoattractant for PMNs, the response to ozone was primarily orchestrated through these cells. However, there are data supporting a role for macrophages in response to ozone. Also, epithelial cells produce stress-induced endogenous ligands, many of which are known to be generated following exposure to ozone, which could interact with innate immune (e.g.CD14, TLR4), complement (e.g. CR3) or other receptors on airway mononuclear cells. An initial experiment by our group shows that ozone challenge of primary epithelial cell cultures (developed from nasal epithelial samplings of volunteers) yield supernatants which activate COX2 and induce IL-6 secretion from peripheral blood monocytes, indicating the potential for an O3-induced, epithelial-derived monocyte ligand. To approach the question of whether low level exposure to ozone modifies airway phagocyte biology (as determined primarily by cell surface marker expression, phagocyte function and endotoxin responsiveness), this study will be similar to the one detailed for endotoxin only volunteers are asked to undergo low level ozone exposure to determine if a priming dose can be identified that modifies monocyte biology but that is sub-threshold for inducing a neutrophil response in the airways.

Exposure to ozone as low as 0.12 ppm for 1 hour without exercise may prime response to allergen, yet is not an otherwise very effective dose for induction of inflammatory or lung function changes. 0.12 ppm O3 for 2 hours with 1 hour of intermittent exercise also does not yield airways inflammation but does result in generation of a salicylate product in volunteers dosed with aspirin which has been proposed as a marker of O3 exposure. Using these and similar studies as a guide, we will perform a study in which volunteers will undergo 0.12 ppm ozone exposure for 2 hours with moderate, intermittent exercise (to yield 35L/min ventilation for a total exercise duration of 1hr). We will examine sputum neutrophil levels (% PMNs and PMN/mg sputum), cell surface marker expression (CD11b, CD14) on sputum and blood inflammatory cells (monocytes, macrophages (sputum), phagocytosis and cytokine response to endotoxin stimulation, 6hr following exposure to ozone.

We will carry out an interim analysis after we have completed study in 6 volunteers to determine if we have identified a level of ozone that is likely to modify mononuclear cell function without significant neutrophilia. If 0.12 ppm of ozone for 2 hours appears to induce a priming response, no change in the PMN response and some modification of monocyte biology, we will continue with that dose. If we see an increase in PMNs, then we will refocus the protocol to challenge volunteers with 0.08 ppm O3 for 2 hours with moderate exercise. If there is no response at the macrophage level, then we would challenge volunteers with 0.2 ppm for 2 hours.

Multiple studies have linked ozone with increased morbidity and mortality. One possible explanation is decreased heart rate variability (HRV). In hospitalized patients, decreased HRV has been directly correlated with increased mortality under multiple conditions. Recent studies completed here have linked particulate matter to decreased HRV. In this study we will evaluate each subject's heart rate variability using ambulatory ECG monitoring.

Hypotheses

  1. Low level ozone will prime airway macrophages/monocytes such that they will be more responsive to inflammatory stimuli, including endotoxin and opsonized zymosan.
  2. Low level ozone will enhance airway and blood monocyte and macrophage function, and induce some alterations in some cell surface markers.
Conditions
Healthy
Being tested
Ozone Exposure
Keywords
Ozone, Healthy Adults

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ozone ExposureDrug

    Low dose ozone exposure in chamber

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Inflammatory markers in sputum

    Measured: post exposure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 May 2007 (estimated)
  2. Study startJun 2009
  3. Primary completionNov 2009
  4. Study completionNov 2009

Why it stopped: Lack of funding

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
0 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00468221
Sponsor's protocol ID
07-0304
Other IDs
R01ES012706, R82952201
Acronym
Lowoz
Status last verified
May 2015
First submitted
30 Apr 2007
Last updated
29 May 2015
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Ozone Exposure in people with Healthy, run by University of North Carolina, Chapel Hill.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: withdrawn, as of the sponsor's last update on 29 May 2015. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study was withdrawn before enrolling participants, so there are no results.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Inflammatory markers in sputum (time frame: post exposure). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 May 2015.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in